During the Constellation Software sell-off, even bullish institutional investors sold their positions. The reason wasn't a change in fundamentals but rather pressure to follow short-term momentum and appease shareholders. This behavior, driven by career risk, creates opportunities for investors focused on long-term business value.

When a stock moves dramatically (e.g., +/- 40%) after news, both the fundamentals and your portfolio weighting have significantly changed. Passively holding the same number of shares is highly unlikely to be the optimal strategy. You must actively re-evaluate and decide whether to add, trim, or sell completely.

Investment gains often come from "multiple expansion," where the market's perception of a business improves, causing it to trade at a higher valuation. This sentiment shift is frequently more impactful than pure earnings growth, and underestimating it is a primary reason for selling winning stocks too early.

Sectors like power generation can trade at low multiples for years. However, when a compelling narrative shift attracts a wave of generalist money, valuations can detach from fundamentals and reach "stupid" levels. This highlights how money flow can be a more powerful driver than traditional valuation metrics.

The market is fixated on the GLP-1 risk, but this is only half the story. The other half of Stevanato's biologics business is growing at 15-18% annually. With 60% of pharma R&D now focused on biologics, the company's recent capacity expansion serves this broader, durable trend, providing a significant buffer.

Traditional valuation metrics are irrelevant. The key is to identify new, impactful information that will bring in a new class of investors and reset the market's perception of the company. This allows for making highly profitable, contrarian bets on stocks that already appear expensive.

The fall of Valiant Pharmaceuticals illustrates that even sophisticated investors can be duped. A charismatic CEO's compelling story, combined with the powerful social proof of a rising stock price, creates a reinforcing narrative that can cause diligent investors to ignore clear warning signs.

The stock price and the narrative around a company are tightly linked, creating wild oscillations. Investors mistakenly equate a rising stock with a great company. In reality, the intrinsic value of a great business rises gradually and steadily, while the stock price swings dramatically above and below this line based on shifting market sentiment.

Despite a strong year for biotech, investors are showing signs of fatigue. This leads them to sell stocks immediately after positive news and financing rounds to lock in gains before year-end, rather than letting positive momentum build further.